Skip to main content
Livermore
Livermore
ZHEN

Bellevue Group AG

SEC CIK
0001674546
Latest filing
Aug 14, 2026

ALNY holding history

Alnylam Pharmaceuticals, Inc. in every 13F filed by Bellevue Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ALNY overviewAll 13F holders of ALNYFull Q2 2026 holdings

Shares (Q2 2026)
1,092
Value
$328.7K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of ALNY by Bellevue Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,092$328.7K<0.1%−233,451−99.5%ReducedHolders
Q1 2026234,543$77.6M1.8%−211,360−47.4%ReducedHolders
Q4 2025445,903$177.3M3.4%−621−0.1%ReducedHolders
Q3 2025446,524$203.6M4.2%−229,843−34.0%ReducedHolders
Q2 2025676,367$220.6M4.9%−91,780−11.9%ReducedHolders
Q1 2025768,147$207.4M4.6%−2,121−0.3%ReducedHolders
Q4 2024770,268$181.3M3.5%−38,827−4.8%ReducedHolders
Q3 2024809,095$222.5M3.6%−110,739−12.0%ReducedHolders
Q2 2024919,834$223.5M3.6%+1,550+0.2%AddedHolders
Q1 2024918,284$137.2M2.1%+32,966+3.7%AddedHolders
Q4 2023885,318$169.5M2.6%−9,027−1.0%ReducedHolders
Q3 2023894,345$158.4M2.6%−5,305−0.6%ReducedHolders
Q2 2023899,650$170.9M2.4%+16,400+1.9%AddedHolders
Q1 2023883,250$176.9M2.6%−37,963−4.1%ReducedHolders
Q4 2022921,213$218.9M2.9%−35,549−3.7%ReducedHolders
Q3 2022956,762$191.5M2.7%−101,424−9.6%ReducedHolders
Q2 20221,058,186$154.3M2.2%−171,377−13.9%ReducedHolders
Q1 20221,229,563$200.8M2.3%−105,577−7.9%ReducedHolders
Q4 20211,335,140$226.4M2.3%−73,278−5.2%ReducedHolders
Q3 20211,408,418$265.9M2.7%−140,674−9.1%ReducedHolders
Q2 20211,549,092$262.6M2.6%−78,022−4.8%ReducedHolders
Q1 20211,627,114$229.7M2.4%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.